Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study

por Wu, Meiyu, Qin, Shuxia, Tan, Chongqing, Li, Sini, Xie, Ouyang, Wan, Xiaomin
Publicado 2023

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis

por wang, Liting, Peng, Ye, Qin, Shuxia, Wan, Xiaomin, Zeng, Xiaohui, Li, Sini, Liu, Qiao, Tan, Chongqing
Publicado 2023

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review

por Wu, Meiyu, Qin, Shuxia, Wang, Liting, Tan, Chongqing, Peng, Ye, Zeng, Xiaohui, Luo, Xia, Yi, Lidan, Wan, Xiaomin
Publicado 2022

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer

por Wu, Meiyu, Qin, Shuxia, Wang, Liting, Tan, Chongqing, Peng, Ye, Zeng, Xiaohui, Luo, Xia, Yi, Lidan, Wan, Xiaomin
Publicado 2022

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study

por Qin, Shuxia, Wang, Xuehong, Li, Sini, Tan, Chongqing, Zeng, Xiaohui, Wu, Meiyu, Peng, Ye, Wang, Liting, Wan, Xiaomin
Publicado 2022

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

por Peng, Ye, Zeng, Xiaohui, Peng, Liubao, Liu, Qiao, Yi, Lidan, Luo, Xia, Li, Sini, Wang, Liting, Qin, Shuxia, Wan, Xiaomin, Tan, Chongqing
Publicado 2021

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

por Peng, Ye, Zeng, Xiaohui, Peng, Liubao, Liu, Qiao, Yi, Lidan, Luo, Xia, Li, Sini, Wang, Liting, Qin, Shuxia, Wan, Xiaomin, Tan, Chongqing
Publicado 2022